- Sutro Biopharma (STRO, Financial) plans to present significant advances in their antibody drug conjugate (ADC) pipeline at the 2025 AACR Annual Meeting.
- The company will focus on STRO-004, showcasing promising preclinical anti-tumor activity with plans for human trials in 2025.
- Sutro's XpressCF+® platform highlights advancements in dual-payload ADCs, enhancing drug-to-antibody ratios and conjugation techniques.
Sutro Biopharma, Inc. (STRO), a leading company in oncology therapies, announced upcoming presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago. The focus will be on their innovative antibody drug conjugate (ADC) programs, particularly the promising preclinical results of STRO-004.
STRO-004, an exatecan Tissue Factor-targeting ADC, demonstrated potent anti-tumor activity and a favorable safety profile in preclinical studies across various dose levels. Notably, a single dose of STRO-004 resulted in encouraging response rates in models of Tissue Factor-positive cancers. Sutro Biopharma intends to move forward with IND-enabling studies, aiming to initiate first-in-human trials later in 2025, marking a crucial step in developing next-generation cancer therapeutics.
In addition to STRO-004, Sutro will showcase its proprietary XpressCF+® platform, which enables the creation of dual-payload ADCs. This platform allows for higher drug-to-antibody ratios and precise, site-selective conjugation of two different payloads. These advancements highlight Sutro’s commitment to innovating ADC technology, potentially overcoming the limitations of conventional ADCs and enhancing treatment efficacy.
CEO Jane Chung expressed enthusiasm about sharing these developments: "Our preclinical data on STRO-004 is very promising, and we are excited to continue exploring its potential as we prepare for clinical trials. Our XpressCF+® platform represents a significant leap forward in ADC development, offering unique capabilities that set our pipeline apart."
The poster presentations are scheduled for April 28, 2025. Dr. Alice Yam will present the preclinical activity and safety data of STRO-004, while Dr. Gang Yin will discuss the advancements in dual-payload ADC technologies. Both presentations underscore Sutro Biopharma’s leading role in developing cutting-edge cancer treatments.
